Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Lutetium Lu 177 dotatate
Synonyms
Therapy Description

Lutathera (lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog that may selectively kill somatostatin receptor-positive tumor cells (PMID: 28076709). Lutathera (lutetium Lu 177 dotatate) is FDA approved for use in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Lutetium Lu 177 dotatate Lutathera LuTate|177Lu-Octreotate|177 Lu-DOTA-Tyr3-octreotate|177Lu-DOTATATE Lutathera (lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog that may selectively kill somatostatin receptor-positive tumor cells (PMID: 28076709). Lutathera (lutetium Lu 177 dotatate) is FDA approved for use in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04106843 Phase II Lutetium Lu 177 dotatate Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers Withdrawn USA 0
NCT02230176 Phase II Sunitinib Lutetium Lu 177 dotatate Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM) Completed FRA 0
NCT04665739 Phase II Everolimus Lutetium Lu 177 dotatate Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Recruiting USA 0
NCT05987176 Phase II Lutetium Lu 177 dotatate Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS) Recruiting GBR 0
NCT03966651 Phase I Lutetium Lu 177 dotatate A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. (NEUROBLU 02) Recruiting FRA 0
NCT02754297 Phase II Lutetium Lu 177 dotatate Personalized PRRT of Neuroendocrine Tumors (P-PRRT) Active, not recruiting CAN 0
NCT05610826 Phase Ib/II Lutetium Lu 177 dotatate Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver Withdrawn USA 0
NCT04903899 Phase II Lutetium Lu 177 dotatate 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N) Recruiting SWE | NOR | NLD | LTU | DNK 0
NCT04614766 Phase Ib/II 131I-MIBG + Lutetium Lu 177 dotatate Lutetium Lu 177 dotatate A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) Withdrawn USA 0
NCT04954820 Phase II Lutetium Lu 177 dotatate Assessment of the Schema of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor (ReLUTH) Recruiting FRA 0
NCT05724108 Phase II Lutetium Lu 177 dotatate Lutetium Lu 177 dotatate + Triapine Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors Recruiting USA 0
NCT07150546 Phase I Lutetium Lu 177 dotatate Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. Not yet recruiting USA 0
NCT05773274 Phase II Everolimus Lutetium Lu 177 dotatate Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial Recruiting USA | CAN 0
NCT03971461 Phase II Lutetium Lu 177 dotatate Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Active, not recruiting USA 0
NCT05691465 Phase II Lutetium Lu 177 dotatate Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells Recruiting USA 0
NCT04529044 Phase II Lutetium Lu 177 dotatate 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Not yet recruiting USA 0
NCT05247905 Phase II Lutetium Lu 177 dotatate Capecitabine + Temozolomide Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting USA 0
NCT06395402 Phase II Lutetium Lu 177 dotatate 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID) Recruiting USA 0
NCT04609592 Phase I Lutetium Lu 177 dotatate Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Recruiting USA 0
NCT06016855 FDA approved Lutetium Lu 177 dotatate Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors Recruiting USA 0
NCT06326190 Phase II Sunitinib Octreotide acetate Hydroxyurea Lutetium Lu 177 dotatate Bevacizumab Everolimus 177Lu-DOTATATE for Recurrent Meningioma (LUMEN-1) Recruiting NOR | FRA | ESP | CHE | AUT 0
NCT04082520 Phase II Lutetium Lu 177 dotatate Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting USA 0


Additional content available in Icon for CKB-BoostCKB BOOST